Protagenic Surges 86 on Phase 1 Trial Progress as 740M Volume Ranks 90th in Market Activity

On August 21, 2025, Protagenic (NASDAQ:PTIX) surged 86.84% with a trading volume of $740 million, ranking 90th in market activity. This sharp rally followed the company’s announcement of advancing its lead candidate, PT00114, into the multiple-dose phase of a Phase 1 trial. The drug, based on Teneurin C-terminus Associated Peptide (TCAP), is designed to modulate stress responses in the amygdala and hippocampus, offering a novel approach to treating anxiety, depression, addiction, and PTSD.

PT00114’s development marks a critical milestone for Protagenic. The compound’s mechanism differentiates it from existing therapies by targeting the root causes of stress-related disorders rather than merely suppressing symptoms. Positive results from a prior single-dose trial demonstrated favorable safety and tolerability, paving the way for rapid progression to Phase 2 efficacy studies in early 2026. Topline safety data is expected by September 2025, with dosing in the multiple-dose trial set to conclude by year-end.

Analysts highlight the strategic significance of PT00114’s pipeline. As a first-in-class TCAP-based therapy, it addresses a substantial unmet need in neuropharmaceuticals, where over 50% of patients report inadequate relief from current treatments. The drug’s potential applications across high-prevalence conditions could attract partnerships, a common catalyst for small-cap biotechs in late-stage clinical trials. Protagenic’s accelerated timeline underscores confidence in the program’s safety profile, which may drive further investor interest ahead of Phase 2 initiation.

Backtesting of a high-volume trading strategy from 2022 to 2025 showed a compound annual growth rate of 6.98%, with a peak-to-trough drawdown of 15.59% recorded in mid-2023. While the approach delivered steady returns, the volatility underscores the need for risk management in volume-driven strategies.